<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36454487</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1860-8965</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Forensic toxicology</Title><ISOAbbreviation>Forensic Toxicol</ISOAbbreviation></Journal><ArticleTitle>Ropinirole involved in a fatal case: blood and urinary concentrations.</ArticleTitle><Pagination><StartPage>173</StartPage><EndPage>179</EndPage><MedlinePgn>173-179</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11419-021-00593-8</ELocationID><Abstract><AbstractText Label="PURPOSE">Ropinirole is an antiparkinsonian&#xa0; drug and has recently been suggested to be effective in amyotrophic lateral sclerosis. It is expected that ropinirole prescriptions will increase in the near&#xa0;future. However, the fatal concentration in blood is unclear at this time. Therefore, we report a fatal case involving ropinirole intoxication and discuss the fatal concentrations with reference to several autopsy cases involving ropinirole.</AbstractText><AbstractText Label="METHODS">Ropinirole was quantified in femoral vein blood, cardiac blood, and urine from five autopsy cases in which ropinirole was detected by drug screening in our laboratory. One is a ropinirole intoxication case (this report) and the others &#xa0;were non-intoxication cases. Their ropinirole concentrations were compared and discussed.</AbstractText><AbstractText Label="RESULTS">The ropinirole concentration in this case was 100&#xa0;ng/mL in femoral blood, 160&#xa0;ng/mL in cardiac blood, and 1840&#xa0;ng/mL in urine. The ropinirole concentrations in the four non-ropinirole poisoning cases were 7-35&#xa0;ng/mL (mean: 24&#xa0;ng/mL) in femoral blood, 13-100&#xa0;ng/mL (mean: 60&#xa0;ng/mL) in cardiac blood, and 140-1090&#xa0;ng/mL (mean: 640&#xa0;ng/mL) in urine. Cardiac/peripheral ratios were in the range of 1.6-2.1 (mean 1.8).</AbstractText><AbstractText Label="CONCLUSIONS">There were no obvious signs of overdose, and the high cardiac/peripheral blood ratio suggested that postmortem redistribution may have occurred, but the &#xa0;peripheral&#xa0;blood ropinirole&#xa0;concentration (100 ng/mL)&#xa0;was obviously higher than that reported in the&#xa0;previous fatal&#xa0;case of ropinirole poisoning (64&#xa0;ng/mL). Based on these results, the cause of death in this case was considered to be shock and fatal arrhythmia due to ropinirole poisoning. This case provides important data on postmortem blood and urinary levels of ropinirole poisoning.</AbstractText><CopyrightInformation>&#xa9; 2021. Japanese Association of Forensic Toxicology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Nagasawa</LastName><ForeName>Sayaka</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0977-5043</Identifier><AffiliationInfo><Affiliation>Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan. nagasawa.s@chiba-u.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Forensic Toxicology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan. nagasawa.s@chiba-u.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yamaguchi</LastName><ForeName>Rutsuko</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saka</LastName><ForeName>Kanju</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torimitsu</LastName><ForeName>Suguru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiba</LastName><ForeName>Fumiko</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yajima</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic Medicine, Graduate School of Medicine, International University of Health and Welfare, Kozunomori 4-3, Narita, 286-8686, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inokuchi</LastName><ForeName>Go</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Motomura</LastName><ForeName>Ayumi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic Medicine, Graduate School of Medicine, International University of Health and Welfare, Kozunomori 4-3, Narita, 286-8686, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kira</LastName><ForeName>Kei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamagishi</LastName><ForeName>Yoshikazu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Toxicology and Environmental Health, Graduate School of Pharmaceutical Sciences, Chiba University, Chuo-ku, Chiba, 260-8675, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ogra</LastName><ForeName>Yasumitsu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Forensic Toxicology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Toxicology and Environmental Health, Graduate School of Pharmaceutical Sciences, Chiba University, Chuo-ku, Chiba, 260-8675, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwase</LastName><ForeName>Hirotaro</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Legal Medicine, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, 260-8670, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Forensic Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Forensic Toxicol</MedlineTA><NlmUniqueID>101315563</NlmUniqueID><ISSNLinking>1860-8965</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001826" MajorTopicYN="Y">Body Fluids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014553" MajorTopicYN="Y">Urinary Tract Physiological Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006321" MajorTopicYN="N">Heart</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amantadine</Keyword><Keyword MajorTopicYN="N">Fatal blood and urinary concentrations</Keyword><Keyword MajorTopicYN="N">LC&#x2013;MS/MS</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">Ropinirole</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>1</Day><Hour>11</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36454487</ArticleId><ArticleId IdType="doi">10.1007/s11419-021-00593-8</ArticleId><ArticleId IdType="pii">10.1007/s11419-021-00593-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rizek P, Kumar N, Jog MS (2016) An update on the diagnosis and treatment of Parkinson disease. CMAJ 188:1157&#x2013;1165. https://doi.org/10.1503/cmaj.151179 (open access article)</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.151179</ArticleId><ArticleId IdType="pubmed">27221269</ArticleId><ArticleId IdType="pmc">5088077</ArticleId></ArticleIdList></Reference><Reference><Citation>Delamarre A, Meissner WG (2017) Epidemiology, environmental risk factors and genetics of Parkinson&#x2019;s disease. Presse Med 46:175&#x2013;181. https://doi.org/10.1016/j.lpm.2017.01.001 (open access article)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lpm.2017.01.001</ArticleId><ArticleId IdType="pubmed">28189372</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2015 Disease and Injury Incidence and Prevalence Collaborators (2016) Global regional and national incidence, prevalence and years lived with disability for 310 disease and injuries, 1990&#x2013;2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1545&#x2013;1602. https://doi.org/10.1016/S0140-6736(16)31678-6001 (open access article)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)31678-6001</ArticleId></ArticleIdList></Reference><Reference><Citation>Marras C, Beck JC, Bower JH, Roberts E, Ritz B, Ross GW, Abbott RD, Savica R, Van Den Eeden SK, Willis AW, Tanner CM, Parkinson&#x2019;s Foundation P4 Group (2018) Prevalence of Parkinson&#x2019;s disease across North America. NPJ Parkinsons Dis 4:21. https://doi.org/10.1038/s41531-018-0058-0 (open access article)</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-018-0058-0</ArticleId><ArticleId IdType="pubmed">30003140</ArticleId><ArticleId IdType="pmc">6039505</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidaihlet MJ, Bonnet AM, Belal S, Dubois B, Marle C, Agid Y (1990) Ropinirole without levodopa in Pakinson&#x2019;s disease. Lancet 336:316&#x2013;317. https://doi.org/10.1016/0140-6736(90)91855-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(90)91855-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, Costa J, Stiasny-Kolster K, Sampaio C (2008) Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 23:2267&#x2013;2302. https://doi.org/10.1002/mds.22254 (open access article)</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22254</ArticleId><ArticleId IdType="pubmed">18925578</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K, Ishikawa M, Otomo A, Atsuta N, Nakamura R, Akiyama T, Hadano S, Aoki M, Saya H, Sobue G, Okano H (2018) Modeling sporadic ALS in IPSC-derived motor neurons identifies a potential therapeutic agent. Nat Med 24:1579&#x2013;1589. https://doi.org/10.1038/s41591-018-0140-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0140-5</ArticleId><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Morimoto S, Takahashi S, Fukushima K, Saya H, Suzuki N, Aoki M, Okano H, Nakahara J (2019) Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis&#x2013;protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial). Regen Ther 11:143&#x2013;166. https://doi.org/10.1016/j.reth.2019.07.002 (open access article)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reth.2019.07.002</ArticleId><ArticleId IdType="pubmed">31384636</ArticleId><ArticleId IdType="pmc">6661418</ArticleId></ArticleIdList></Reference><Reference><Citation>Okano H, Yasuda D, Fujimori K, Morimoto S, Takahashi S (2020) Ropinirole, a new ALS drug candidate developed using iPSCs. Trends Pharmacol Sci 41:99&#x2013;109. https://doi.org/10.1016/j.tips.2019.12.002 (open access article)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2019.12.002</ArticleId><ArticleId IdType="pubmed">31926602</ArticleId></ArticleIdList></Reference><Reference><Citation>Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52:1908&#x2013;1910. https://doi.org/10.1212/wnl.52.9.1908</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.52.9.1908</ArticleId><ArticleId IdType="pubmed">10371546</ArticleId></ArticleIdList></Reference><Reference><Citation>Duband S, Bidat C, Gaillard Y, Rochet M, Camdessanche JP, P&#xe9;oc&#x2019;h M (2012) A fatal intoxication case involving ropinirole. J Forensic Leg Med 19:422&#x2013;425. https://doi.org/10.1016/j.jflm.2012.04.013 &#xa0;</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jflm.2012.04.013</ArticleId><ArticleId IdType="pubmed">22920767</ArticleId></ArticleIdList></Reference><Reference><Citation>Simk&#xf3; J, Szentandr&#xe1;ssy N, Harmati G, B&#xe1;r&#xe1;ndi L, Horv&#xe1;th B, Magyar J, B&#xe1;ny&#xe1;sz T, L&#xf3;rincz I, N&#xe1;n&#xe1;si PP (2010) Effects of ropinirole on action potential characteristics and the underlying ion currents in canine ventricular myocytes. Naunyn Schmied Arch Pharmacol 382:213&#x2013;220. https://doi.org/10.1007/s00210-010-0538-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00210-010-0538-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giacopo R, Fasano A, Fenici R, Loria G, Bentivoglio AR (2010) Rare and serious cardiac side effects during ropinirole titration. Mov Disord 25:1509&#x2013;1510. https://doi.org/10.1002/mds.23115</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23115</ArticleId><ArticleId IdType="pubmed">20629152</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagasawa S, Saka K, Yamagishi Y, Yajima D, Chiba F, Yamaguchi R, Torimitsu S, Iwase H (2021) Association between sexual activity-related death and non-prescription use of phosphodiesterase type 5 inhibitors. Leg Med 48:101815. https://doi.org/10.1016/j.legalmed.2020.101815</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.legalmed.2020.101815</ArticleId></ArticleIdList></Reference><Reference><Citation>Usui K, Hayashizaki K, Hashiyada M, Funayama M (2012) Rapid drug extraction from human whole blood using a modified QuEChERS extraction method. Leg Med 14:286&#x2013;296. https://doi.org/10.1016/j.legalmed.2012.04.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.legalmed.2012.04.008</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Veterinary Medicine (2018) Bioanalytical method validation: guidance for industry. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf . Accessed 24 May 2018</Citation></Reference><Reference><Citation>Nishikawa N, Nagai M, Moritoyo T, Yabe H, Nomoto M (2009) Plasma amantadine concentrations in patients with Parkinson&#x2019;s disease. Parkinsonism Relat Disord 15:351&#x2013;353. https://doi.org/10.1016/j.parkreldis.2008.08.005 (open access article)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2008.08.005</ArticleId><ArticleId IdType="pubmed">18823813</ArticleId></ArticleIdList></Reference><Reference><Citation>Sande MA, Mandell GL (1980) Antimicrobial agents, chap 54. In: Goodman and Gilman&#x2019;s the pharmacological basic of therapeutic, 6th edn. Macmillan Publishers, New York, p 1241</Citation></Reference><Reference><Citation>Schulz M, Schmoldt A, Andersen-Streichert H, Iwersen-Bergmann S (2020) Revisited: therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics. Crit Care 24:195. https://doi.org/10.1186/s13054-020-02915-5 (open access article)</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-02915-5</ArticleId><ArticleId IdType="pubmed">32375836</ArticleId><ArticleId IdType="pmc">7201985</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalpe-Scott M, Degouffe M, Garbutt D, Drost M (1955) A comparison of drug concentrations in postmortem cardiac and peripheral blood in 320 cases. Can Soc Sci J 28:113&#x2013;121. https://doi.org/10.1080/00085030.1995.10757474</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00085030.1995.10757474</ArticleId></ArticleIdList></Reference><Reference><Citation>Tompson DJ, Vearer D (2007) Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson&#x2019;s disease. Clin Ther 29:2654&#x2013;2666. https://doi.org/10.1016/j.clinthera.2007.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2007.12.010</ArticleId><ArticleId IdType="pubmed">18201581</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori N, Hasegawa K, Sakamoto T (2012) Pharmacokinetics and effect of food after oral administration of prolonged release tablets of ropinirole hydrochloride in Japanese patients with Parkinson&#x2019;s disease. J Clin Pharm Ther 37:571&#x2013;577. https://doi.org/10.1111/j.1365-2710.2012.01336.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2710.2012.01336.x</ArticleId><ArticleId IdType="pubmed">22390368</ArticleId></ArticleIdList></Reference><Reference><Citation>Perea E, Robbins BV, Hutto B (2006) Psychosis related to ropinirole. Am J Psychiatry 163:547&#x2013;548. https://doi.org/10.1176/appi.ajp.163.3.547</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.163.3.547</ArticleId><ArticleId IdType="pubmed">16513886</ArticleId></ArticleIdList></Reference><Reference><Citation>Navacerrada F, Gonz&#xe1;lez-Alonso MR, Alonso-Navarro H, Pilo-de-la-Fuente B, Plaza-Nieto JF, Jim&#xe9;nez-Jim&#xe9;nez FJ (2011) Liver toxicity possibly related with ropinirole use in the treatment of restless legs syndrome. Eur J Neurol 18:e65. https://doi.org/10.1111/j.1468-1331.2010.03317.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2010.03317.x</ArticleId><ArticleId IdType="pubmed">21199184</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannelli M, Lazzeri C, Ianni L, La Villa G, Pupilli C, Bellini F, Serio M, Franchi F (1997) Dopamine and sympathoadrenal activity in man. Clin Exp Hypertens 19:163&#x2013;179. https://doi.org/10.3109/10641969709080813</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10641969709080813</ArticleId><ArticleId IdType="pubmed">9028644</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh T-L, Yang Y-K, Chiu N-T, Yao W-J, Yeh S-J, Wu J-S, Chuang J-I, Chang SH (2006) Correlation between striatal dopamine D<sub>2</sub>/D<sub>3</sub> receptor binding and cardiovascular activity in healthy subjects. Am J Hypertens 19:964&#x2013;969. https://doi.org/10.1016/j.amjhyper.2006.03.005 (open access article)</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjhyper.2006.03.005</ArticleId><ArticleId IdType="pubmed">16942941</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurst RS, Higdon NR, Lawson JA, Clark MA, Rutherford-Root KL, McDonald WG, Haas JV, McGrath JP, Meglasson MD (2003) Dopamine receptor agonists differ in their actions on cardiac ion channels. Eur J Pharmacol 482:31&#x2013;37. https://doi.org/10.1016/j.ejphar.2003.09.054</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2003.09.054</ArticleId><ArticleId IdType="pubmed">14660002</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey SJ, Turman CN, Curry JT, Wheeler GJ (2006) Cardiovascular and electrocardiographic effects of the dopamine receptor agonists ropinirole, apomorphine, and PNU-142774E in conscious beagle dogs. J Cardiovasc Pharmacol 47:337&#x2013;347. https://doi.org/10.1097/01.fjc.0000205983.05771.f5</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.fjc.0000205983.05771.f5</ArticleId><ArticleId IdType="pubmed">16633074</ArticleId></ArticleIdList></Reference><Reference><Citation>Baselt RC (2017) Disposition of toxic drugs and chemicals in man, 11th edn. Biomedical Publications, Seal Beach, p 1805</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>